



## BSW Formulary Updates and Recent Decisions – February 2024

### New additions to BSWformulary and Change in Traffic Light Status

- **Drospirenone 4mg film coated tablets (Slynd®)** added with **GREEN** TLS as a second line progesterone only pill (POP). Drospirenone POP is more expensive than alternative POPs. It offers a different bleeding pattern and side effect profile (lower androgenic profile) for individuals that have had problems with other POPs. There are some additional medical eligibility considerations because drospirenone is potassium-sparing. Read the FSRH statement for more information [FSRH CEU Statement: Drospirenone Progestogen-only Pill \(DRSP POP\) \(Jan 24\) - Faculty of Sexual and Reproductive Healthcare](#)
- **Medi Derma S Barrier Cream 28g and 90g tube 20 x 2g sachets** added with **GREEN** TLS. Procure through direct supply route where possible. Also see [BSW Skin Care Pathway for IAD/MASD](#).

### New and Updated Shared Care Agreements and Prescribing Guidance

- **UPDATE – Lithium for patients within adult services** this SCA, is now in the format of the national shared care protocol templates and has been adopted by BNSSG and BSW so is applicable to all areas AWP cover.
- **UPDATE – BSW Prescribing criteria for DOACs in VTE in adults** – **apixaban** is now first choice for DVT and PE management for new patients. Please note, the BEMS internal guidance is being updated and a link to this will follow shortly.
- **NEW – Glucose management in adults with T2D (includes tirzepatide)** – New guidance includes a flow chart, in line with NICE guidance, to inform primary care treatment pathway. It has been approved by the BSW diabetes specialists and local DSN's. Note that tirzepatide is now available in UK wholesalers as 2.5mg and 5mg Mounjaro® KwikPen® formulations. See formulary entry [here](#) for more information on tirzepatide.
- **UPDATE – Initiating SGLT2's for adults in Type 2 diabetes and in Chronic Kidney Disease**. Minor update to existing guideline.
- **UPDATE – BSW Prescribing Guidance for Moderately to Severely Frail Patients**. Minor typographical changes including updated link to revised [PrescQIPP IMPACT tool](#).
- **NEW/UPDATE – Primary Care Migraine Treatment Pathway** – existing guidance reformatted and simplified. Guidance now includes a flowchart and updated information on valproate prescribing. Candesartan has been reclassified from amber to green for migraine prophylaxis indication. [Formulary \(bswformulary.nhs.uk\)](#). The **Secondary Care Biologic Migraine Prevention Pathway** has also been updated.



### **What the BSW ICB formulary team are currently working on**

- An application for the use of cytisine 1.5mg tablets for use in smoking cessation.
- Working with local partners on a BSW continence and urology product formulary.
- Working with our commissioners to review tier 3 obesity services in order to provide the semaglutide option in line with [NICE TA875](#).
- Working as a collaborative Integrated Care System (ICS) diabetes group to implement Hybrid Closed Loop system provision in line with [NICE TA943](#).
- Supporting the primary care team with a BSW LES review.
- Reviewing the current BSW Sativex policy.

*The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email [bswicb.formulary@nhs.net](mailto:bswicb.formulary@nhs.net)*